Orthofix Q3 Loss Narrows to $6.1M, but Nine-Month Cash Burn Reaches $61M
OFIX is trading near its 52-week low of $7.81 (15% below the low) on elevated volume (2.0× avg).
Summary
Orthofix's Q3 loss narrowed to $6.1M ($0.15/share) on $207.9M of sales, but nine-month free cash flow was negative $61.3M and debt rose to $221.8M after a $65M term-loan draw. The 10-Q also reveals that the board ratified CEO equity awards that breached the incentive plan's share sublimit.
Key Events · Earnings and Guidance · OFIX
-
Q3 Sales Growth Slows to 1.1%
Net sales came in at $207.9M versus $205.6M a year ago, as Global Spine fell 0.4% while Global Limb Reconstruction grew 8.5%.
-
Loss Narrows on Lower Legal Costs
The net loss was $6.1M ($0.15/share) versus $22.8M ($0.57), helped by a $22.8M reduction in SG&A tied to legal matters; adjusted EBITDA was $26.0M.
-
Nine-Month Cash Burn and Debt Build
Operating cash flow was -$23.5M and free cash flow -$61.3M, funded by a $65.0M Term B draw that lifted long-term debt to $221.8M from $157.4M; cash stood at $86.3M.
-
Board Ratifies Excess CEO Equity Awards
Directors ratified 441,695 equity awards (241,695 potentially putative stock) granted to the CEO above the 2012 LTIP sublimit and raised the annual sublimit to 1,000,000 shares.
Analysis · OFIX · Industrial Applications And Services
With the $0.15-a-share loss already out via Dow Jones this morning, the incremental news sits in the details. Sales growth has slowed to 1.1% reported, operating cash flow flipped to a $23.5M outflow for the nine months, and free cash flow is negative $61.3M against $86.3M of cash. That burn was funded by drawing the $65.0M Term B loan in January, lifting long-term debt to $221.8M. Most of the quarter's profit improvement came from a $22.8M drop in legal costs rather than operations, so it is not a repeatable earnings improvement. Separately, the board had to ratify 441,695 equity awards to the CEO that were granted above the plan's share sublimit — a governance misstep disclosed here for the first time.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OFIX was trading at $6.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $320.6M. The 52-week trading range was $7.81 to $16.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.